One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Immutep Limited
IMMP · NGM · Healthcare · Biotechnology
Current price
$3.23
52-week range
$3.06 - $70.60
Market cap
$23.80M
Balance sheet
Healthy
-1,201.72x Concerning
Net cash $47.12M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -77.3% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 0.0% (peer median: 1.0%).
What this company does
Immutep Limited
Immutep Limited is a biotechnology company that creates new medicines to help the body's own immune system fight cancer and autoimmune diseases. Their main focus is on a specific type of drug that targets something called LAG-3, which helps control immune responses. The money they make comes from developing these experimental treatments, and what matters is how successful their drug trials are because that determines if they can eventually sell these medicines.
How the company got here
Immutep Limited, originally founded in 1987 as Prima BioMed Ltd, has evolved into a clinical-stage biotechnology company focused on developing innovative immunotherapies. The company changed its name to Immutep in November 2017 to better reflect its core focus on lymphocyte activation gene-3 (LAG-3) related therapies. This strategic shift marked a new chapter, concentrating its efforts on harnessing the immune system to fight cancer and autoimmune diseases. Its journey has involved extensive research and development, leading to a pipeline of potential treatments currently in various stages of clinical trials.
What it actually does
Immutep is in the business of creating new medicines, specifically treatments that help the body's own immune system fight diseases like cancer. They focus on a specific target in the immune system called LAG-3, which acts like a brake on immune responses. By developing therapies that can release this brake, Immutep aims to enable the immune system to more effectively attack cancer cells. Their work involves complex biological research and testing these potential drugs in human clinical trials to see if they are safe and effective.
Immunotherapies (LAG-3 related)
This is Immutep's primary business, centered around developing treatments that leverage the LAG-3 pathway to treat cancer and autoimmune diseases. Their lead product candidate, eftilagimod alfa (efti), is a fusion protein designed to block the LAG-3 immune checkpoint, thereby boosting the immune system's ability to fight tumors. The company is investigating efti in various cancer types, including breast cancer and head and neck cancer, through multiple clinical trials. This segment represents the core of Immutep's operations and its future potential, with significant investment in research and development to advance these drug candidates through regulatory approval.
What management is betting on now
Immutep's management is heavily focused on advancing its lead product candidate, eftilagimod alfa, through late-stage clinical trials for various cancer indications. A key priority is demonstrating the efficacy and safety of efti, particularly in combination with other cancer treatments, to gain regulatory approval. The company is also exploring new applications for its LAG-3 technology and expanding its pipeline with other drug candidates targeting immune-related diseases. Success in these clinical trials is crucial for securing partnerships and ultimately bringing these novel therapies to patients.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $3.23
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $47.1M - more cash than debt. Interest coverage -1201.7x.
Net debt
$-47.12M
Interest coverage
-1,201.72x
Immutep Limited's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
IMMP
BASELINE
Immutep Limited
Total debt $727.70K Interest coverage -1,201.72x This is the baseline the peer rows are being compared against.
Total debt $367.81M Interest coverage -7.38x Neither company has much profit cushion over interest right now.
Total debt $3.02M Interest coverage 1,160.22x This peer still has a real interest-payment cushion, while IMMP does not.
Total debt $148.35M Interest coverage -0.26x Neither company has much profit cushion over interest right now.
What you should know
The case for and against IMMP
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -77.3% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 0.0% (peer median: 1.0%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.62x
P/B
0.55x
P/S
1.19x
EV/EBITDA
0.56x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
-255.7%
Net margin
0.0%
ROE
-77.3%
ROA
-42.5%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
5.69x
Quick ratio
5.54x
Total debt
$727.70K
Total cash
$47.85M
Growth
How the business has been compounding
Revenue TTM
$13.85M
Revenue 5Y CAGR
340.4%
EPS TTM
-7.30
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-30.53M
Free CF TTM
$-38.59M
FCF margin
-278.7%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—